Aligos Therapeutics
On September 20, 2024, we posted a press release stating that Aligos Therapeutics (ALGS) announced successful topline results from a phase 2A HERALD study of ALG-055009, a thyroid hormone receptor . . .
This content is for paid subscribers.
Impacting News
October 16, 2024
